This review aims to evaluate the efficacy of any vitamin administration(s) in preventing and managing COVID-19 and/or long-COVID. Databases were searched up to May 2023 to identify randomized clinical trials comparing data on the effects of vitamin supplementation(s) versus placebo or standard of care on the two conditions of interest. Inverse-variance random-effects meta-analyses were conducted to estimate pooled risk ratios (RRs) and 95% confidence intervals (CIs) for all-cause mortality between supplemented and non-supplemented individuals. Overall, 37 articles were included: two regarded COVID-19 and long-COVID prevention and 35 records the COVID-19 management. The effects of vitamin D in preventing COVID-19 and long-COVID were contrasting. Similarly, no conclusion could be drawn on the efficacy of multivitamins, vitamin A, and vitamin B in COVID-19 management. A few positive findings were reported in some vitamin C trials but results were inconsistent in most outcomes, excluding all-cause mortality (RR = 0.84; 95% CI: 0.72-0.97). Vitamin D results were mixed in most aspects, including mortality, in which benefits were observed in regular administrations only (RR = 0.67; 95% CI: 0.49-0.91). Despite some benefits, results were mostly contradictory. Variety in recruitment and treatment protocols might explain this heterogeneity. Better-designed studies are needed to clarify these vitamins' potential effects against SARS-CoV-2.

The efficacy of multivitamin, vitamin a, vitamin b, vitamin c, and vitamin d supplements in the prevention and management of Covid-19 and long-Covid. An updated systematic review and meta-analysis of randomized clinical trials / Sinopoli, A.; Sciurti, A.; Isonne, C.; Santoro, M. M.; Baccolini, V.. - In: NUTRIENTS. - ISSN 2072-6643. - 16:9(2024), pp. 1-38. [10.3390/nu16091345]

The efficacy of multivitamin, vitamin a, vitamin b, vitamin c, and vitamin d supplements in the prevention and management of Covid-19 and long-Covid. An updated systematic review and meta-analysis of randomized clinical trials

Sinopoli A.;Sciurti A.
;
Isonne C.;Baccolini V.
2024

Abstract

This review aims to evaluate the efficacy of any vitamin administration(s) in preventing and managing COVID-19 and/or long-COVID. Databases were searched up to May 2023 to identify randomized clinical trials comparing data on the effects of vitamin supplementation(s) versus placebo or standard of care on the two conditions of interest. Inverse-variance random-effects meta-analyses were conducted to estimate pooled risk ratios (RRs) and 95% confidence intervals (CIs) for all-cause mortality between supplemented and non-supplemented individuals. Overall, 37 articles were included: two regarded COVID-19 and long-COVID prevention and 35 records the COVID-19 management. The effects of vitamin D in preventing COVID-19 and long-COVID were contrasting. Similarly, no conclusion could be drawn on the efficacy of multivitamins, vitamin A, and vitamin B in COVID-19 management. A few positive findings were reported in some vitamin C trials but results were inconsistent in most outcomes, excluding all-cause mortality (RR = 0.84; 95% CI: 0.72-0.97). Vitamin D results were mixed in most aspects, including mortality, in which benefits were observed in regular administrations only (RR = 0.67; 95% CI: 0.49-0.91). Despite some benefits, results were mostly contradictory. Variety in recruitment and treatment protocols might explain this heterogeneity. Better-designed studies are needed to clarify these vitamins' potential effects against SARS-CoV-2.
2024
covid-19; randomized clinical trials; systematic review; vitamin
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
The efficacy of multivitamin, vitamin a, vitamin b, vitamin c, and vitamin d supplements in the prevention and management of Covid-19 and long-Covid. An updated systematic review and meta-analysis of randomized clinical trials / Sinopoli, A.; Sciurti, A.; Isonne, C.; Santoro, M. M.; Baccolini, V.. - In: NUTRIENTS. - ISSN 2072-6643. - 16:9(2024), pp. 1-38. [10.3390/nu16091345]
File allegati a questo prodotto
File Dimensione Formato  
Sinopoli_efficacy_2024.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 2.61 MB
Formato Adobe PDF
2.61 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1724314
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 6
social impact